Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
DOWNLOAD MEDIA RELEASE Baar, Switzerland--(Newsfile Corp. - September 15, 2026) - medmix has secured an "A" rating in CDP's Supplier Engagement Assessment for the second consecutive year, placing the company among a select group of global leaders recognized for driving climate action across their supply chains. CDP's Supplier Engagement Assessment evaluates how companies manage climate-related risk across their supply chains, based on disclosures in CDP's annual Climate...
DOWNLOAD MEDIA RELEASE Baar, Switzerland--(Newsfile Corp. - September 10, 2026) - medmix’ Drug Delivery (“Haselmeier”) announces its collaboration with Xeris Pharmaceuticals to support the development of Xeris’ XP-8121 product candidate, an investigational once-weekly subcutaneous levothyroxine therapy in development for the treatment of hypothyroidism. XP-8121 combines a proprietary high-concentration XeriSol® levothyroxine formulation with an adjustable pen injector designed...
DOWNLOAD MEDIA RELEASE DOWNLOAD IMAGE FleXa™ Baar, Switzerland--(Newsfile Corp. - July 9, 2026) - medmix introduces FleXa™, a new customizable syringe platform that advances precision and branding for single-component dental materials. This modular system combines usability with flexible design options to help manufacturers differentiate in a competitive market. FleXa™ offers manufacturers over 150 medical-grade colors, custom color matching, and design options such as...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.